Clinical Trial Update: Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study of MLN2480 in relapsed/refractory solid tumors with dose expansion in metastatic melanoma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Solid Tumor

Drugs mentioned

• MLN2480 (MLN2480)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Melanoma, Metastatic Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2020-08-10